The International Cohort Study of Children Born to Women Infected with Zika Virus (ZIKV) During Pregnancy study is a prospective, observational, international cohort study of children previously enrolled in the ZIP study or other ZIP 2.0 Protocol Team approved ZIKV-cohort study that will continue the longitudinal follow-up of children born with documented confirmed or presumptive in-utero ZIKV exposure ("ZIKV-exposed" cohort) and children born without documented confirmed or presumptive in-utero ZIKV exposure, matched by site and birth sex ("ZIKV-unexposed" cohort). Follow-up evaluations and assessments will allow for the determination and comparison of long-term neurodevelopmental outcomes among in utero ZIKV-exposed and ZIKV-unexposed children. Each participant will be followed for about 2 years, beginning at approximately 18 months through 42 months of age.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Neurodevelopmental outcome at age18 months
Timeframe: At enrollment
Neurodevelopmental outcome at age 24 months
Timeframe: Six months after enrollment
Neurodevelopmental outcome at age 30 months
Timeframe: Twelve months after enrollment
Neurodevelopmental outcome at age 36 months
Timeframe: Eighteen months after enrollment.
Neurodevelopmental outcome at age 42 months
Timeframe: Twenty four months after enrollment